Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240870 | 1.00 | KMT2A (0.33) | KMT2ASMN1; SMN2CYP3A4SLC7A5S1PR1 | |
| SCHEMBL21690268 | 1.00 | KMT2A (0.33) | KMT2ASMN1; SMN2CYP3A4SLC7A5S1PR1 | |
| Hydrochloric Acid SCHEMBL10596638 | 0.98 | KMT2A (0.33) | KMT2ASMN1; SMN2 | |
| SCHEMBL1310344 | 0.80 | SLC22A6 (0.33) | SMN1; SMN2 | |
| SCHEMBL17846594 | 0.79 | L3MBTL1 (0.39) | KMT2ASMN1; SMN2 | |
| SCHEMBL12348365 | 0.76 | GRM1 (0.35) | KMT2ACYP3A4SLC7A5 | |
| SCHEMBL19175517 | 0.76 | GRM1 (0.35) | KMT2ACYP3A4SLC7A5 | |
| SCHEMBL10943354 | 0.75 | — | — | |
| SCHEMBL17773069 | 0.75 | ALDH1A1 (0.31) | CYP3A4 | |
| SCHEMBL8522594 | 0.74 | CPB2 (0.38) | KMT2ACYP3A4GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114423304-A | Compositions and methods for improvement and maintenance of weight loss | 雀巢产品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-112752575-A | Use of histidine, glycine and other amino acids for the prevention of insulin resistance and/or diabetes | 雀巢产品有限公司 | 2021-05-04 | — | — | CN | disclosed |
| CN-112740045-A | Markers for the risk of developing insulin resistance in childhood and adolescence | 雀巢产品有限公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2019178141-A1 | ORGANIC METABOLITE COMPOSITIONS AND METHODS OF USE AS MITICIDES FOR HONEY BEES | NIEMCZURA PAUL (US) | 2019-09-19 | — | — | WO | disclosed |
| US-9668973-B2 | Components for producing amphoteric liposomes | MARINA BIOTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | MARINA BIOTECH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8580297-B2 | Components for producing amphoteric liposomes | MARINA BIOTECH, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120100205-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | MARINA BIOTECH, INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | PHOSPHO1, SGMS1, CHMP4B | KMT2A 3725/4885SMN1; SMN2 4767/4885CYP3A4 4083/4885 |
| US-20120100205-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | PHOSPHO1, SGMS1, CHMP4B | KMT2A 3725/4885SMN1; SMN2 4767/4885CYP3A4 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.